# First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes

> **NCT04259801** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 152 (actual)

## Conditions studied

- Healthy Volunteers
- Overweight
- Obesity
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** NNC0480-0389
- **DRUG:** Semaglutide
- **DRUG:** Placebo (NNC0480-0389)
- **DRUG:** Placebo (semaglutide)

## Key facts

- **NCT ID:** NCT04259801
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-17
- **Primary completion:** 2022-03-16
- **Final completion:** 2022-03-16
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2023-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04259801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04259801, "First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04259801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*